Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents in Subjects With Myelodysplastic Syndrome and Acute Myeloid Leukaemia

Trial Profile

A Phase I/II Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents in Subjects With Myelodysplastic Syndrome and Acute Myeloid Leukaemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; GSK 3326595 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Nov 2019 According to trial design data of this trial released in the 61st Annual Meeting and Exposition of the American Society of Hematology, ten participants have been enrolled, all into Part 1.
    • 06 Nov 2019 Trial design data of this trial, was released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Jan 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top